Historical Valuation
Trinity Biotech PLC (TRIB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 0.52. The fair price of Trinity Biotech PLC (TRIB) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.73 USD , Trinity Biotech PLC is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：0.73
Fair
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Trinity Biotech PLC (TRIB) has a current Price-to-Book (P/B) ratio of -0.28. Compared to its 3-year average P/B ratio of -2.45 , the current P/B ratio is approximately -88.53% higher. Relative to its 5-year average P/B ratio of -37.46, the current P/B ratio is about -99.25% higher. Trinity Biotech PLC (TRIB) has a Forward Free Cash Flow (FCF) yield of approximately -37.71%. Compared to its 3-year average FCF yield of -48.14%, the current FCF yield is approximately -21.68% lower. Relative to its 5-year average FCF yield of -17.38% , the current FCF yield is about 116.97% lower.
P/B
Median3y
-2.45
Median5y
-37.46
FCF Yield
Median3y
-48.14
Median5y
-17.38
Competitors Valuation Multiple
AI Analysis for TRIB
The average P/S ratio for TRIB competitors is 1.88, providing a benchmark for relative valuation. Trinity Biotech PLC Corp (TRIB.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of 3.24%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TRIB
1Y
3Y
5Y
Market capitalization of TRIB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TRIB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TRIB currently overvalued or undervalued?
Trinity Biotech PLC (TRIB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 0.52. The fair price of Trinity Biotech PLC (TRIB) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.73 USD , Trinity Biotech PLC is Undervalued By Fair .
What is Trinity Biotech PLC (TRIB) fair value?
TRIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Trinity Biotech PLC (TRIB) is between +Inf to +Inf according to relative valuation methord.
How does TRIB's valuation metrics compare to the industry average?
The average P/S ratio for TRIB's competitors is 1.88, providing a benchmark for relative valuation. Trinity Biotech PLC Corp (TRIB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 3.24%, this premium appears unsustainable.
What is the current P/B ratio for Trinity Biotech PLC (TRIB) as of Jan 11 2026?
As of Jan 11 2026, Trinity Biotech PLC (TRIB) has a P/B ratio of -0.28. This indicates that the market values TRIB at -0.28 times its book value.
What is the current FCF Yield for Trinity Biotech PLC (TRIB) as of Jan 11 2026?
As of Jan 11 2026, Trinity Biotech PLC (TRIB) has a FCF Yield of -37.71%. This means that for every dollar of Trinity Biotech PLC’s market capitalization, the company generates -37.71 cents in free cash flow.
What is the current Forward P/E ratio for Trinity Biotech PLC (TRIB) as of Jan 11 2026?
As of Jan 11 2026, Trinity Biotech PLC (TRIB) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Trinity Biotech PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Trinity Biotech PLC (TRIB) as of Jan 11 2026?
As of Jan 11 2026, Trinity Biotech PLC (TRIB) has a Forward P/S ratio of 0.00. This means the market is valuing TRIB at $0.00 for every dollar of expected revenue over the next 12 months.